VPS34 Inhibitors Block Double Membrane Vesicle Formation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for COVID-19 and other coronavirus infections lack effective methods to inhibit viral replication and transmission, particularly targeting the formation of double membrane vesicles essential for viral replication and spread.

Innovation Solution

Administration of VPS34 inhibitors, which target the formation of double membrane vesicles required for viral replication and spread, thereby inhibiting viral entry, replication, and trafficking.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for COVID-19 are used, then viral replication and transmission continue unchecked, but no effective method exists to inhibit viral replication and transmission by targeting double membrane vesicle formation

Engineering Contradiction:

Improveeffectiveness of viral replication inhibitionVSAvoidavailability of therapeutic approaches

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by identifying and targeting the specific biochemical parameter of VPS34 kinase activity, which is essential for double membrane vesicle formation. By using VPS34 inhibitors to modulate this kinetic parameter, the invention achieves effective inhibition of viral replication and transmission, resolving the contradiction between reliability of treatment and availability of therapeutic approaches.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If VPS34 inhibitors are administered, then formation of double membrane vesicles is blocked and viral replication is inhibited, but this represents a novel therapeutic approach that was previously unavailable

Engineering Contradiction:

Improveinhibition of viral replicationVSAvoidnovelty of therapeutic approach

Core Design Contradiction:

ProductivityVSAdaptability or versatility

Solution Approach 1:

The patent extracts and isolates the specific function of VPS34 kinase in double membrane vesicle formation from the complex viral replication process. By targeting this specific extracted function with VPS34 inhibitors, the invention achieves high productivity in inhibiting viral replication while providing a novel therapeutic approach that addresses the unmet medical need for coronavirus treatments.

Inventive Principle:

Principle #2Taking out (Extraction)

3Object-affected harmful factors

If double membrane vesicles are formed, then viral RNA is protected from host cell RNAases and viral replication proceeds, but blocking this formation with VPS34 inhibitors prevents viral spread

Engineering Contradiction:

Improveprotection of viral RNA from degradationVSAvoidviral transmission and spread

Core Design Contradiction:

Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful protective function of double membrane vesicles into a beneficial target for inhibition. By using VPS34 inhibitors to block vesicle formation, the invention transforms the vesicles' protective role (harmful to treatment) into a specific target that, when inhibited, benefits patient outcomes by preventing viral replication and transmission.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS11801238B2Anti-viral activity of VPS34 inhibitors

Publication Date: 2023.10.31 DECIPHERA PHARMACEUTICALS LLC

AI summary

Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor.